Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study

Lorenzo Fuccio, Loredana Correale, Alberto Arezzo, Alessandro Repici, Gianpiero Manes, Cristina Trovato, Benedetto Mangiavillano, Mauro Manno, Claudio Camillo Cortelezzi, Marco Dinelli, Vincenzo Cennamo, Mario De Bellis, Annalisa Altimari, Giulio Cariani, Angelo Caruso, Rita Conigliaro, Cristiano Crosta, Paolo Delrio, Maria Cristina Di Marco, Carlo FabbriMichelangelo Fiorentino, Stefania Ghersi, Elisa Gruppioni, Cesare Hassan, Liboria Laterza, Guglielmo Nasti, Carmine Pinto, Fabiola Rojas, Eleonora Scaioli

Research output: Contribution to journalArticle

Abstract

Background: This study aimed to explore the relationship between K-ras status, anti-tumour treatments, and the complications of colorectal self-expandable metallic stenting in colorectal cancer. Methods: This is a retrospective, multicentre study of 91 patients with obstructive advanced colorectal cancer palliated with enteral stents between 2007 and 2011. Results: K-ras wild-type tumours were diagnosed in 44 patients (48.4%); 82 (90.1%) received chemotherapy and 45 (49.4%) had additional biological therapy (34 bevacizumab, 11 cetuximab). Twenty-one (23.1%) experienced stent-related complications: 11 (52.4%) occurred in the K-ras mutant group (P= 0.9). K-ras wild-type patients were not less likely to develop adverse events than K-ras mutant patients (OR, 0.99; 95% CI: 0.4-2.7). Overall mean time to complication was 167.6 days (range 4-720 days), with no difference between the two groups (141 vs. 197 days; P= 0.5). Chemotherapy did not influence the risk of complications (OR, 0.56; 95% CI: 0.14-2.9), and there was no evidence that patients treated with chemotherapy and cetuximab were more likely to experience stent-related complications than patients treated with chemotherapy alone, or untreated (OR, 1.2; 95% CI: 0.2-5.9). Although perforation rates were higher with bevacizumab-based treatment (11.8% vs. 7%), this result was not statistically significant (P= 0.69). Conclusions: K-ras mutation status, chemotherapy, and biological treatments should not influence colorectal stent-related complication rates.

Original languageEnglish
Pages (from-to)561-567
Number of pages7
JournalDigestive and Liver Disease
Volume46
Issue number6
DOIs
Publication statusPublished - 2014

Keywords

  • Bevacizumab
  • Cetuximab
  • Colorectal cancer
  • K-ras mutation status
  • Occlusion
  • Self-expandable metal stent

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study'. Together they form a unique fingerprint.

  • Cite this

    Fuccio, L., Correale, L., Arezzo, A., Repici, A., Manes, G., Trovato, C., Mangiavillano, B., Manno, M., Cortelezzi, C. C., Dinelli, M., Cennamo, V., De Bellis, M., Altimari, A., Cariani, G., Caruso, A., Conigliaro, R., Crosta, C., Delrio, P., Di Marco, M. C., ... Scaioli, E. (2014). Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 46(6), 561-567. https://doi.org/10.1016/j.dld.2014.02.006